Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 3;12:3549. doi: 10.1038/s41598-022-07597-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Performance of the sVNT ELISA in fully vaccinated individuals in comparison to convalescent patients. (A) Comparison of PRNT₅₀ and binding inhibition in vaccinated individuals (N = 112). Data points are color-coded according to the GenScript sVNT results and in-house cutoffs: blue (< 15% = negative), gray (≥ 15 to < 35% = equivocal) and orange (≥ 35% = positive). Samples with titers above the PRNT quantification limit ( >) are marked in yellow. (B) Comparison between sVNT and PRNT (PRNT₅₀) in vaccinated (blue; N = 90) versus convalescent (light orange; N = 242; data from Fig. 1C) individuals, including only PRNT-positive samples. (C) Distribution of the sVNT-binding inhibition results in vaccinated (N = 112) and convalescent individuals (N = 242). (D) Distribution of PRNT₅₀ titers in vaccinated (N = 90) and convalescent (N = 242) individuals. (E) Time difference between symptom onset or vaccination (N = 90) and convalescent (N = 75) individuals for whom the period between symptom onset or vaccination and sampling was known. Statistics: t-test, ***p ≤ 0.001.